Distinct CD44 splice variants differentially affect collateral artery growth

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 13-20

  Bot, Pieter T ^a,b   Grundmann, Sebastian ^a,b,d   van Royen, Niels ^b   Joosten, Sander P J ^b   Schirmer, Stephan H ^b,e   de Kleijn, Dominique P V ^c   Pals, Steven T ^b   Pasterkamp, Gerard ^a   Piek, Jan J ^b   Hoefer, Imo E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

Arteriogenesis; CD44; Cell migration; Cellular adhesion; Hyaluronic acid

Indexed keywords

CD44V ANTIGEN; HEPARAN SULFATE; HERMES ANTIGEN; MESSENGER RNA;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; EXON; FEMORAL ARTERY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UPREGULATION;

EID: 84873179959     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547584     Document Type: Article

References (33)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
2. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543-53.
3. Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a metaanalysis. Eur Heart J 2011; 33: 614-21.
4. Schaper W. Collateral vessels reduce mortality. Eur Heart J 2012; 33: 564-6.
5. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101: 40-50.
6. Cai W, Vosschulte R, Afsah-Hedjri A, et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 2000; 32: 997-1011.
7. Hoefer I, van Royen N, Buschmann I, Piek J, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 2001; 49: 609-17.
8. Schaper J, Koenig R, Franz D, Schaper W. The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes. A combined SEM and TEM study. Virchows Arch A (Pathol Anat) 1976; 370: 193-205.
9. van Royen N, Hoefer I, Bottinger M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003; 92: 218-25.
10. van Royen N, Voskuil M, Hoefer I, et al. CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization. Circulation 2004; 109: 1647-52.
11. Cuff CA, Kothapalli D, Azonobi I, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001; 108: 1031-40.
12. DeGrendele H, Estess P, Picker L, Siegelman M. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183: 1119-30.
13. Jones M, Tussey L, Athanasou N, Jackson D. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 2000; 275: 7964-74.
14. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest 1998; 101: 97-108.
15. Sherman L, Wainwright D, Ponta H, Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 1998; 12: 1058-71.
16. van der Voort R, Taher TE, Wielenga VJ, et al. Heparan sulfatemodified CD44 promotes hepatocyte growth factor/scatter factorinduced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999; 274: 6499-506.
17. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992 Dec 15; 89: 12160-4.
18. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
19. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO 1991; 10: 343-8.
20. Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 2006; 26: 362-70.
21. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002; 420: 691-5.
22. Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 2001; 20: 3821-30.
23. Watermann DO, Tang Y, Zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 2006; 66: 4774-80.
24. Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998; 273: 338-43.
25. Bennett KL, Modrell B, Greenfield B, et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995; 131: 1623-33.
26. van der Voort R, Manten-Horst E, Smit L, Ostermann E, van den Berg F, Pals ST. Binding of cell-surface expressed CD44 to hyaluronate is dependent on splicing and cell type. Biochem Biophys Res Commun 1995; 214: 137-44.
27. Bennett K, Jackson D, Simon J, et al. CD44 isoformas containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128: 687-98.
28. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cellderived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743-51.
29. te Riele H, Maandag ER, Berns A. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci USA 1992; 89: 5128-32.
30. Deindl E, Boengler K, van Royen N, Schaper W. Differential expression of GAPDH and beta3-actin in growing collateral arteries. Mol Cell Biochem 2002; 236: 139-46.
31. Forster-Horvath C, Meszaros L, Raso E, et al. Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo. Microvasc Res 2004; 68: 110-8.
32. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993; 268: 12235-8.
33. Wittig BM, Stallmach A, Zeitz M, Gunthert U. Functional involvement of CD44 variant 7 in gut immune response. Pathobiology 2002; 70: 184-9.